Adverum Biotechnologies IncNASDAQ:ADVM
- LAST PRICE7.3500
- TODAY'S CHANGE (%)-0.1000 (-1.3423%)
- Bid / Lots7.2200/ 1
- Ask / Lots7.9400/ 1
- Open / Previous Close7.4000 / 7.4500
- Day Range
- 52 Week Range
- Volume93,793
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADVM |
|---|---|---|
| 09:32 ET | 4504 | 7.44 |
| 09:36 ET | 1300 | 7.37 |
| 09:38 ET | 648 | 7.36 |
| 09:39 ET | 100 | 7.36 |
| 09:50 ET | 150 | 7.36 |
| 10:01 ET | 6865 | 7.33 |
| 10:15 ET | 700 | 7.33 |
| 10:17 ET | 500 | 7.36 |
| 10:21 ET | 200 | 7.3786 |
| 10:26 ET | 1164 | 7.4 |
| 10:32 ET | 314 | 7.409 |
| 10:35 ET | 2200 | 7.4299 |
| 10:37 ET | 100 | 7.41 |
| 10:39 ET | 100 | 7.41 |
| 10:44 ET | 100 | 7.39 |
| 10:51 ET | 400 | 7.4 |
| 10:57 ET | 100 | 7.39 |
| 11:02 ET | 300 | 7.4 |
| 11:11 ET | 771 | 7.33 |
| 11:13 ET | 1000 | 7.34 |
| 11:27 ET | 100 | 7.34 |
| 11:31 ET | 100 | 7.355 |
| 11:33 ET | 100 | 7.36 |
| 11:40 ET | 100 | 7.36 |
| 11:42 ET | 800 | 7.365 |
| 11:44 ET | 100 | 7.37 |
| 11:47 ET | 100 | 7.385 |
| 11:51 ET | 200 | 7.37 |
| 11:54 ET | 100 | 7.385 |
| 12:00 ET | 161 | 7.3864 |
| 12:02 ET | 1805 | 7.37 |
| 12:05 ET | 200 | 7.37 |
| 12:16 ET | 100 | 7.35 |
| 12:27 ET | 5219 | 7.35 |
| 12:34 ET | 2759 | 7.335 |
| 12:39 ET | 1100 | 7.32 |
| 12:45 ET | 480 | 7.33 |
| 12:56 ET | 100 | 7.32 |
| 01:03 ET | 100 | 7.32 |
| 01:08 ET | 100 | 7.33 |
| 01:14 ET | 100 | 7.32 |
| 01:15 ET | 1425 | 7.31 |
| 01:17 ET | 2369 | 7.3 |
| 01:19 ET | 578 | 7.32 |
| 01:30 ET | 1513 | 7.3254 |
| 01:35 ET | 100 | 7.3 |
| 01:37 ET | 433 | 7.315 |
| 01:39 ET | 100 | 7.3075 |
| 01:44 ET | 293 | 7.314 |
| 01:46 ET | 100 | 7.3 |
| 01:48 ET | 100 | 7.315 |
| 01:50 ET | 1751 | 7.2788 |
| 01:51 ET | 152 | 7.29 |
| 01:55 ET | 400 | 7.27 |
| 02:00 ET | 1048 | 7.28 |
| 02:02 ET | 620 | 7.3 |
| 02:04 ET | 300 | 7.29 |
| 02:06 ET | 200 | 7.3 |
| 02:22 ET | 400 | 7.3 |
| 02:24 ET | 200 | 7.3 |
| 02:31 ET | 100 | 7.27 |
| 02:33 ET | 300 | 7.32 |
| 02:44 ET | 100 | 7.295 |
| 02:47 ET | 200 | 7.32 |
| 02:49 ET | 400 | 7.335 |
| 02:58 ET | 100 | 7.36 |
| 03:03 ET | 100 | 7.36 |
| 03:12 ET | 388 | 7.35 |
| 03:21 ET | 570 | 7.325 |
| 03:34 ET | 400 | 7.35 |
| 03:36 ET | 100 | 7.37 |
| 03:41 ET | 1914 | 7.38 |
| 03:43 ET | 1266 | 7.33 |
| 03:45 ET | 700 | 7.33 |
| 03:48 ET | 400 | 7.33 |
| 03:50 ET | 400 | 7.32 |
| 03:52 ET | 600 | 7.33 |
| 03:54 ET | 1638 | 7.355 |
| 03:56 ET | 732 | 7.35 |
| 03:57 ET | 470 | 7.36 |
| 03:59 ET | 8968 | 7.35 |
May 15, 2024
DJ Adverum Biotechnologies Is Maintained at Buy by Truist Securities, from 2:32PM ET on Wednesday May 15, 2024 by Dow Jones
2:32PM ET on Wednesday May 15, 2024 by Dow Jones
May 10, 2024
DJ Adverum Biotechnologies Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 8:42AM ET on Friday May 10, 2024 by Dow Jones
8:42AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow Jones*DJ Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adverum Biotechnologies Inc | 164.4M | -0.7x | --- |
bluebird bio Inc | 172.0M | -1.2x | --- |
Sagimet Biosciences Inc | 170.1M | -3.8x | --- |
Abeona Therapeutics Inc | 180.4M | -1.3x | --- |
Atossa Therapeutics Inc | 163.5M | -5.3x | --- |
Outlook Therapeutics Inc | 165.5M | -0.6x | --- |
Company Information
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Contact Information
- Headquarters
- 100 Cardinal WayREDWOOD CITY, CA, United States 94063
- Phone
- 650-649-1004
- Fax
- 650-329-8151
Executives
- Independent Chairman of the Board
- Patrick Machado
- President, Chief Executive Officer, Director
- Laurent Fischer
- Chief Financial Officer
- Linda Rubinstein
- Chief Operating Officer
- Kishor Soparkar
- Chief Technology Officer
- Andrew Ramelmeier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $160.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-10.23 |
Book Value | $8.23 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
